Palivizumab Eligibility — RACP Paediatrics MCQ

Instant feedback + full explanation. One question, done properly.

ModerateRespiratoryPalivizumab EligibilityRACP Paediatrics

A premature infant born at 27 weeks is now 12 months corrected age and has chronic lung disease requiring home oxygen. What respiratory pathogen should prophylaxis be considered for?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — RSV (palivizumab)

Palivizumab (anti-RSV monoclonal antibody) prophylaxis is recommended for high-risk infants including those with chronic lung disease of prematurity who are <12 months corrected age during the RSV season. It reduces RSV hospitalisation rates by approximately 50%.

Reference: RCH Melbourne – 2024 – Clinical Practice Guidelines: RSV Prophylaxis